morning i received news release nord good news living kennedy disease treatment discovered would hate see something works tied red tape long approval process last two paragraphs news release summarize findings reason study landmark nord study concludes fda flexible reviewing therapies rare diseases study catalogues flexibility orphan drugs approved since washington dc october national organization rare disorders nord today released landmark report documenting flexibility food drug administration fda review potential treatments patients rare diseases released conference rare diseases orphan products report examined basis fda approval non cancer orphan drugs rare diseases since orphan drug enacted provide incentives encourage development treatments rare diseases first study kind ever conducted first time systematic examination basis approval category drug products extending long period time study demonstrates decades long pattern flexibility fda review orphan drugs frank sasinowski chairman nord board directors author report said wanted determine whether fda requires orphan drug applications provide conventional effectiveness data ordinarily expected drugs prevalent diseases whether agency years exercised flexibility approving drugs patients rare diseases issue critical patients families nord serves patient population available testing orphan drugs definition limited drugs prevalent diseases nord president ceo peter l saltonstall said gratified extensive study spearheaded nord behalf entire rare disease community found supportable evidence document flexibility fda medical reviewers study provide extra level confidence investigators companies investors considering developing new drugs rare diseases disease affecting fewer americans defined law rare many rare diseases affect hundred dozen people conducting clinical studies required develop treatments diseases poses special challenges medical researchers report pointed nord study looked drugs diseases cancer approved orphans since identify flexibility employed review process evaluation process distinguishes flexibility applied result previously described fda system accelerated approval program case case basis non cancer drugs approved orphans since nord sought access fda approval letter labeling time approval decision memoranda fda officials approved products reviews medical statistical officers documents retrievable cases subsets documents recoverable drugs especially earliest approved orphan therapies drugs divided three categories nord judgment would met traditional data requirements effectiveness whose approval based flexibility applied result documented fda system flexibility whose approval appeared reflect case case flexibility drug approvals studied nord concluded would met traditional data requirements reflected administrative flexibility based previously documented fda system reflected flexibility applied case case basis review fda actions concludes two every three orphan drugs approved show fda historic flexibility review effectiveness data orphan drug therapies sasinowski said therefore fda demonstrated actions orphan products recognizes importance therapies persons rare disorders would helpful flexibility importance recognized formal fda policy fda officials incorporate recognize flexibility systematic way evaluations new therapy development fda review americans rare disease saltonstall added nord undertook study nearly known rare diseases fda approved treatments better understanding regulatory process pathways likely lead increased study rare diseases safe effective treatments patients important said